美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

VanEck Biotech ETF

231.17

+0.46970.20%

盤前：231.03-0.1434-0.06%08:23 EDT

成交量：3,421

成交額：79.19萬

市值：4.64億

市盈率：- -

高：231.68

開：231.68

低：231.17

收：230.70

52周最高：244.35

52周最低：160.91

股本：200.65萬

流通股本：200.65萬

量比：0.42

換手率：0.17%

股息：0.95

股息率：0.41%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Revolution Medicines旗下Rasonque美國正式上市，30天療程批發採購價39,800美元——電話會議披露

美國FDA批准Revolution Medicines旗下Rasonque™（Daraxonrasib）上市，開創轉移性胰腺癌廣譜Ras靶向治療先河

BUZZ——美國股市動態-Revolution Medicines、Abercrombie & Fitch、Williams-Sonoma

Revolution Medicines的胰腺癌藥物 Daraxonrasib已獲得美國監管機構的批准，這是首款針對胰腺

美國食品藥品監督管理局（FDA）批准了Revolution Medicines公司的一款胰腺癌藥物

歐盟委員會擴大吉利德Trodelvy®在轉移性三陰性乳腺癌一線治療中的應用範圍，覆蓋所有PD-L1狀態

吉利德科學：歐盟批准Trodelvy聯合Keytruda用於一線PD-L1陽性轉移性三陰性乳腺癌

美國聯邦貿易委員會（FTC）：安進專利申請收購交易受到反壟斷審查。

Piper Sandler上調安進目標價至457美元

美國研究綜述-安進、Analog Devices、莫德納

福泰製藥(VRTX)股票8月19日收盤上漲4.48%：釋放什麼信號？

TradingKey中文

吉利德科學(GILD)股票8月19日盤中上漲3.66%：背後推手曝光

TradingKey中文

安進(AMGN)股票8月19日盤中上漲3.19%：背後推手曝光

TradingKey中文

再生元製藥旗下Pasatru獲歐洲藥品管理局審評，全球申報在即

再生元製藥獲FDA批准：Pasatru（Garetosmab-Grts）上市，治療成人進行性骨化性纖維發育不良

瑞穗上調安進目標價至352美元

藥代違規進入診療區域！湘雅二醫院發藥品「停用函」，艾力斯、賽諾菲、安進、康蒂尼四藥企上「黑榜」

TScan Therapeutics披露：安進將終止與其研究合作及許可協議

吉利德科學(GILD)股票8月18日盤中上漲3.14%：背後推手曝光

TradingKey中文

EyePoint股價料將創下歷史最大跌幅，因其一款實驗性眼科藥物未能達到後期臨床試驗目標

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/BBH/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","market":"US","secType":"STK","nameCN":"VanEck Biotech ETF","latestPrice":231.1734,"timestamp":1789588800000,"preClose":230.7037,"halted":0,"volume":3421,"hourTrading":{"tag":"盘前","latestPrice":231.03,"preClose":231.1734,"latestTime":"08:23 EDT","volume":31,"amount":7162.073219999999,"timestamp":1789647809022,"change":-0.1434,"changeRate":-0.00062,"amplitude":0.00062},"delay":0,"changeRate":0.002035944807127016,"floatShares":2006503,"shares":2006503,"eps":0,"marketStatus":"盤前交易","change":0.4697,"latestTime":"09-17 08:58:48 EDT","open":231.68,"high":231.68,"low":231.1734,"amount":791940.974,"amplitude":0.002196,"askPrice":265.51,"askSize":100,"bidPrice":199.58,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":231.1734,"sharesOutstanding":1976503,"nav":230.79718,"aum":463095224.42,"dividendRate":0.0041,"bidAskSpread":0.001036,"preHourTrading":{"tag":"盘前","latestPrice":231.03,"preClose":231.1734,"latestTime":"08:23 EDT","volume":31,"amount":7162.073219999999,"timestamp":1789647809022,"change":-0.1434,"changeRate":-0.00062,"amplitude":0.00062},"postHourTrading":{"tag":"盘后","latestPrice":231.35,"preClose":231.1734,"latestTime":"19:30 EDT","volume":14,"amount":3236.4276,"timestamp":1789601405727,"change":0.1766,"changeRate":0.000764,"amplitude":0},"volumeRatio":0.4224604161320307,"impliedVol":0.1729,"impliedVolPercentile":0.24},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBH\",,,,,undefined,":{"symbol":"BBH","floatShares":2006503,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.4224604161320307,"shares":2006503,"dividePrice":0.9478,"high":231.68,"amplitude":0.002196,"preClose":230.7037,"low":231.1734,"week52Low":160.91,"pbRate":"--","week52High":244.345,"institutionHeld":0,"latestPrice":231.1734,"eps":0,"divideRate":0.0041,"volume":3421,"delay":0,"ttmEps":0,"open":231.68,"prevYearClose":189.2649,"prevWeekClose":229.3922,"prevMonthClose":236.396,"prevQuarterClose":203.2373,"fiveDayClose":231.22,"twentyDayClose":224.4799,"sixtyDayClose":189.3704},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBH","amount":0.9565,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-12-23","symbol":"BBH","amount":1.2517,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"VanEck Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-24","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-24"},{"date":"2023-12-18","symbol":"BBH","amount":0.7127,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"VanEck Biotech ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"BBH","amount":0.7488,"defaultRemindTime":1671460200000,"name":"VanEck Biotech ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"BBH","amount":0.3972,"defaultRemindTime":1640010600000,"name":"VanEck Vectors Biotech ETF","recordDate":"2021-12-27","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-19","recordDate":"2016-12-21","paymentDate":"2016-12-23","value":0.327,"currency":"USD"},{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.006,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-30","value":0.4724,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-28","value":0.6079,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-27","value":0.3972,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBH\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1164882019","title":"Revolution Medicines旗下Rasonque美國正式上市，30天療程批發採購價39,800美元——電話會議披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1164882019","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164882019?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 01:57","pubTimestamp":1787767031,"startTime":"0","endTime":"0","summary":"Revolution Medicines公司日前宣布，其研发的Rasonque药物现已在美国市场正式商业化供应。这款产品的批发采购成本定为39,800美元，对应30天的用药剂量。值得注意的是，此次上市定价反映了Rasonque在精准肿瘤治疗领域的差异化价值主张。从商业角度看，这一价格策略也释放出Revolution Medicines对其产品竞争力的强烈信心。分析人士指出，随着Rasonque正式进入流通渠道，相关供应链与市场准入工作已全面启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","PTH","BBH","IE00B2B36J28.USD","IDNA","IE00B4R5TH58.HKD","IE0002141913.USD","BK4139","LU0109394709.USD","CANC","IE0009354923.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","RVMD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156385670","title":"美國FDA批准Revolution Medicines旗下Rasonque™（Daraxonrasib）上市，開創轉移性胰腺癌廣譜Ras靶向治療先河","url":"https://stock-news.laohu8.com/highlight/detail?id=1156385670","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156385670?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 01:00","pubTimestamp":1787763644,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局正式批准了Revolution Medicines研发的Rasonque——这标志着全球首款针对转移性胰腺癌的广谱Ras靶向药物成功问世。此举不仅为晚期胰腺癌患者带来了全新的治疗选项，更在肿瘤精准医疗领域树立起一座重要的里程碑。此次获批，无疑将深刻影响胰腺癌治疗的现有格局。对于广大深受胰腺癌困扰的患者群体而言，Rasonque的上市，无疑为他们与病魔的抗争增添了一件有力武器。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","PTH","BK4139","BBH","CANC","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0002141913.USD","IDNA","LU0109394709.USD","RVMD","IE0009355771.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662436927","title":"BUZZ——美國股市動態-Revolution Medicines、Abercrombie & Fitch、Williams-Sonoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2662436927","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662436927?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 23:45","pubTimestamp":1787759102,"startTime":"0","endTime":"0","summary":".N美国东部时间11:30，道琼斯工业平均指数.DJI下跌0.25%，报53,444.86点。标普500指数.SPX下跌0.02%，报7,675.90点；纳斯达克综合指数.IXIC下跌0.20%，报26,098.72点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4S44N1B5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","LU0889565916.HKD","RVMD","PTH","BK4139","IE0009355771.USD","IE00B2B36J28.USD","LU0942090050.USD","CANC","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU0109394709.USD","BK4094","LU0170899867.USD","BK4585","IE0002141913.USD","IE00BJT1NW94.SGD","BK4178","LU0868494708.USD","BBH","LU0320765992.SGD","IE00BFTCPJ56.SGD","WSM","ANF","BK4588","LU0868494617.USD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662482997","title":"Revolution Medicines的胰腺癌藥物 Daraxonrasib已獲得美國監管機構的批准，這是首款針對胰腺","url":"https://stock-news.laohu8.com/highlight/detail?id=2662482997","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662482997?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 23:14","pubTimestamp":1787757271,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BBH","IE00B2B36J28.USD","BK4139","IE0009354923.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","CANC","LU0109394709.USD","PTH","IE0009355771.USD","RVMD","IDNA","IE0002141913.USD","LU0889565916.HKD","LU0320765992.SGD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662271008","title":"美國食品藥品監督管理局（FDA）批准了Revolution Medicines公司的一款胰腺癌藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2662271008","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662271008?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 22:44","pubTimestamp":1787755452,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）批准了Revolution Medicines公司的一款胰腺癌药物路透8月26日-美国食品药品监督管理局周三表示，已批准Revolution Medicines公司用于治疗转移性胰腺癌的靶向药物RVMD.O。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4T44N176:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","IDNA","IE0002141913.USD","IE00B4R5TH58.HKD","PTH","IE0009354923.USD","BBH","BK4139","IE00BJT1NW94.SGD","IE00B2B36J28.USD","CANC","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186632498","title":"歐盟委員會擴大吉利德Trodelvy®在轉移性三陰性乳腺癌一線治療中的應用範圍，覆蓋所有PD-L1狀態","url":"https://stock-news.laohu8.com/highlight/detail?id=1186632498","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186632498?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 18:32","pubTimestamp":1787567559,"startTime":"0","endTime":"0","summary":"欧盟委员会近日作出重要决定，将吉利德科学（Gilead Sciences）旗下重磅药物Trodelvy®的适用范围进一步拓宽。此次调整聚焦于转移性三阴性乳腺癌的一线治疗领域，且不再受限于患者的PD-L1表达状态。这一举措意味着，无论生物标志物检测结果如何，符合条件的患者均有望从该疗法中获益。此举不仅为临床医生提供了更为灵活的用药选择，也标志着Trodelvy®在肿瘤治疗版图中的地位得到显著提升。吉利德科学方面对此表示积极回应，认为该批准将助力满足更多患者未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","LU1066053197.SGD","LU1778281490.HKD","IE00BKVL7J92.USD","IE00B19Z3581.USD","LU0882574055.USD","LU0122379950.USD","IE00B19Z3B42.SGD","LU0058720904.USD","MEDI","GILD","LU2087621335.USD","TMED","LU1571399168.USD","LU1674673691.USD","BK4578","BK4588","BK4532","BBH","LU2357627491.SGD","BK4585","IE0002270589.USD","BIB","LU1430594728.SGD","LU0320765992.SGD","LU1037948541.HKD","LU1934455277.USD","LU0965509283.SGD","LU2089984988.USD","IE00BZ1G4Q59.USD","BK4568","LU0114720955.EUR","LU1057294990.SGD","LU1839511570.USD","LU1066051498.USD","LU0289739699.SGD","LU1934455863.HKD","LU2112291526.USD","LU0859254822.USD","LU0965509101.SGD","LU0234570918.USD","LU1061106388.HKD","SG9999015986.USD","SG9999015945.SGD","IE00B7SZLL34.SGD","LU0823416689.USD","BK4566","LU0861579265.USD","SG9999015952.SGD","TBXU","LU0965509010.AUD","IE00B3T34201.USD","LU0889565916.HKD","LU2468319806.SGD","LU0965508806.USD","IBBQ","BK4583","IBB","SG9999015978.USD","LU1585245621.USD","LU2324357040.USD","LU1023059063.AUD","LU1037948897.HKD","LU1934455194.USD","BK4139","LU0109394709.USD","IE00BSNM7G36.USD","BK4550","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193380081","title":"吉利德科學：歐盟批准Trodelvy聯合Keytruda用於一線PD-L1陽性轉移性三陰性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1193380081","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193380081?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 18:32","pubTimestamp":1787567533,"startTime":"0","endTime":"0","summary":"吉利德科学公司宣布，欧盟已正式授予其抗体药物偶联物Trodelvy与默沙东的Keytruda联合用药方案的上市许可。这一批准针对的是既往未经治疗的PD-L1阳性转移性三阴性乳腺癌患者群体。此项授权标志着该联合疗法在欧盟地区的临床可及性迈出关键一步，为这类侵袭性强、治疗选择有限的乳腺癌亚型患者提供了新的一线治疗选项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455277.USD","LU1057294990.SGD","IE00BSNM7G36.USD","BK4139","LU2087621335.USD","BK4566","IE00B19Z3581.USD","BK4578","BK4588","BBH","LU2468319806.SGD","LU0965508806.USD","IE00B3T34201.USD","LU1934455863.HKD","LU0122379950.USD","LU1934455194.USD","LU1674673691.USD","LU1430594728.SGD","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU0823416689.USD","LU1023059063.AUD","LU1066053197.SGD","LU0889565916.HKD","LU0965509010.AUD","LU1066051498.USD","TMED","BK4532","LU0109394709.USD","LU0861579265.USD","LU2089984988.USD","LU2112291526.USD","LU0289739699.SGD","LU0114720955.EUR","BK4568","LU1778281490.HKD","IE00B7SZLL34.SGD","LU0234570918.USD","LU1674673428.USD","IE0002270589.USD","LU1585245621.USD","LU0965509283.SGD","LU1037948897.HKD","LU2357627491.SGD","LU0320765992.SGD","SG9999015952.SGD","LU1571399168.USD","IBBQ","BK4550","BIB","SG9999015945.SGD","GILD","LU0058720904.USD","MEDI","BK4585","LU1037948541.HKD","TBXU","LU0965509101.SGD","LU0859254822.USD","LU0882574055.USD","IBB","LU1061106388.HKD","SG9999015978.USD","BK4583","LU1839511570.USD","LU2324357040.USD","IE00BZ1G4Q59.USD","BMED","SG9999015986.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661291370","title":"美國聯邦貿易委員會（FTC）：安進專利申請收購交易受到反壟斷審查。","url":"https://stock-news.laohu8.com/highlight/detail?id=2661291370","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661291370?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 23:49","pubTimestamp":1787327356,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GGTL","JHCS","EMQQ","ARB","RSPT","MSFY","AMGN","BBH","HCA","QQMG","DISC","NBDS","DRUP","JHMT","PJP","PBS","PBE","GXPC","MUSQ","WEBX","TGRW","MNA","IHF","MSFX","BUYO","CWC","BCTK","GOOX","WEBL","FTC","ORCZ","IXP","NBCC","FCOM","IBBQ","IEME","BIB","EVNT","MRGR","TBXU","XLCI","BWEB","TRUC","KEMQ","ONEQ","GXPT","IBB","TDAQ","PNQI","LRGG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661250489","title":"Piper Sandler上調安進目標價至457美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661250489","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661250489?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 15:20","pubTimestamp":1787296801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IBB","LU1983299246.USD","BK4581","IE00BJJMRZ35.SGD","IBBQ","BIB","UUP","BK4534","BK4588","BK4566","LU2242646821.SGD","LU1571399168.USD","IE00B2B36J28.USD","LU0868494617.USD","LU0320765992.SGD","LU2089984988.USD","LU0889565916.HKD","IE0009355771.USD","BK4139","AMGN","IE00B4R5TH58.HKD","LU2112291526.USD","LU1061106388.HKD","LU0109394709.USD","LU0122379950.USD","PBE","BBH","LU1023059063.AUD","LU0058720904.USD","LU2242652126.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","TBXU","LU0289739699.SGD","IE00BJT1NW94.SGD","PJP","LU1057294990.SGD","UDN","BK4585","BK4533","IE0002141913.USD","BK4599","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660043834","title":"美國研究綜述-安進、Analog Devices、莫德納","url":"https://stock-news.laohu8.com/highlight/detail?id=2660043834","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660043834?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 15:49","pubTimestamp":1787212153,"startTime":"0","endTime":"0","summary":"美国研究综述-安进、Analog Devices、莫德纳路透8月20日-周四，华尔街证券分析师上调了多家在美国上市公司的评级和目标股价，其中包括安进、模拟设备公司和莫德纳。股票按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nL4S44H0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1935043536.SGD","LU2125909759.SGD","LU2129689514.USD","LU1935042991.SGD","LU0444973449.USD","IE00B1BXHZ80.USD","VHT","IE00B19Z9P08.USD","LU0417517546.SGD","LU0943347566.SGD","LU1670711123.USD","LU0823417653.USD","LU2506951958.HKD","LU0006306889.USD","LU1084165304.USD","LU2361044865.SGD","SNOU","LU2506951875.HKD","LU2360032135.SGD","LU1235294995.USD","BK4097","PSWD","GLAM","SOXY","IHF","LU1585245621.USD","LU1989764664.SGD","LU0114720955.EUR","LU1169590202.USD","LU0061475181.USD","IE0000B7K699.USD","LU2133065610.SGD","LU2487616109.SGD","LU1623119135.USD","LU1037948897.HKD","SG9999015945.SGD","SGXZ57979304.SGD","IE0002141913.USD","JDOC","LU0795875169.SGD","LU0433182093.SGD","LU2237443978.SGD","LU1162221912.USD","LU2517655374.HKD","LU1267930573.SGD","IE00BD6J9T35.USD","MRVL","LU0708994859.HKD","LU2237443622.USD","MRNX","LU1989763005.USD","LU2552382058.USD","LU1992135472.HKD","TGT","LU2357305700.SGD","LU0786609619.USD","LU1069347547.HKD","LU0081259029.USD","LU0823434583.USD","LU1066051811.HKD","LU2112291526.USD","LU2543165471.USD","LU0128525689.USD","MRVX","BK4560","LU1732799900.SGD","GDOC","SG9999001440.SGD","LU1035773651.USD","LU2458330243.SGD","LU1923622291.USD","SG9999003800.SGD","LU0820561909.HKD","LU1551013425.SGD","BK4114","PCTY","IE000BZT7R73.USD","LU0861579265.USD","LU2125154935.USD","LU2322448791.USD","PJP","LU0320765646.SGD","IE00B5949003.HKD","LU1803068979.SGD","IE00BSNM7G36.USD","LU2041044095.USD","LU2242646821.SGD","LU1718418525.SGD","IE0004086264.USD","LU0029864427.USD","LU1732800096.USD","LU2458330169.SGD","LU0690374961.EUR","LU1169589451.USD","BK4533","LU0077335932.USD","CRWC","BIB","BK4505","BK4585","LU1978683503.SGD","BK4550","LU2023250843.SGD","LU2361045086.USD","IE00BFTCPJ56.SGD","LU2125909916.SGD","LU0109392836.USD","LU2087621335.USD","BK4141","LU2322448957.HKD","LU0203345920.USD","LU2404859741.USD","BK4551","LU1861215975.USD","LU0738911758.USD","LU0985320562.USD","LU1839511570.USD","MRVU","AGNG","LU1992135399.USD","IHE","DTCR","SG9999001176.USD","LU0265550359.USD","LU1941712348.USD","LU2473716301.USD","IE00B2B36J28.USD","LU1023059063.AUD","LU2098885051.SGD","WDNA","LU1823568750.SGD","BK4596","SG9999000418.SGD","BK4501","BK4568","CRWL","LU1093756325.SGD","LU1691799644.USD","IYH","LU1923623000.USD","SG9999002232.USD","LU0950375773.USD","MRNY","LU0211328371.USD","BK4130","IE00B19Z3581.USD","IE0009355771.USD","LOW","SG9999015952.SGD","LU2272731865.HKD","SG9999001176.SGD","LU0154236417.USD","IE000WAW04H5.SGD","IE00BDGV0183.EUR","IE00BMPRXN33.USD","LU1291159041.SGD","GNOM","MRK","BK4515","IE00B19Z3B42.SGD","LU1712237335.SGD","LU0124384867.USD","BK4116","IE00BN8TJ469.HKD","LU2237443895.HKD","LU1244550494.USD","LU0256863811.USD","LU0965509010.AUD","LU1804176565.USD","HAKY","BK4094","LU0942090050.USD","LU1934455277.USD","LU1951200564.SGD","LU0053666078.USD","LU0127658192.USD","LU0130517989.USD","LU0949170772.SGD","LU0052756011.USD","LU0057025933.USD","MRNA","SG9999014021.USD","LU2089284900.SGD","LU0726765562.USD","LU1923622614.USD","LU2552382132.HKD","HRTS","LU0238689110.USD","BK4559","LU2125909247.SGD","LU1267930490.SGD","LU2491050071.SGD","LU0310799852.SGD","ARTY","LU0661504455.SGD","SG9999015358.SGD","LU0868494617.USD","BK4588","LU1674673428.USD","DAT","FXL","LU1670710661.SGD","CIBR","SG9999014005.SGD","LU1852331112.SGD","SG9999014013.SGD","LU1303367103.USD","IE00BZ1G4Q59.USD","LU1989772923.USD","LU1670710588.SGD","SG9999014575.USD","LU2433249047.HKD","IGV","BK4535","LU2506952170.USD","LU0256863902.USD","SG9999014039.USD","BK4503","IE0004445239.USD","LU0724618433.USD","LU0302445910.USD","BK4558","LU0274383776.USD","LU2361044949.HKD","LU0444971666.USD","MVLL","LU0957808578.USD","SNOW","LU0985489474.SGD","LU2023250504.SGD","LU1699723380.USD","BK4083","LU1670627923.USD","LU1316542783.SGD","LU2360106780.USD","BK4566","LU0878866978.SGD","LU0234572021.USD","LU1983299246.USD","LU0098860793.USD","LU0069063385.USD","FTXH","XNTK","BK4139","LU2089283258.USD","SG9999015986.USD","LU1941712264.USD","LU1244550577.SGD","LU0094547139.USD","LU1929549753.HKD","BK4516","IE00B42XCP33.USD","IE0004091025.USD","LU1571399168.USD","LU2517655028.SGD","LU0689472784.USD","SG9999002224.SGD","FHLC","LU1642822529.SGD","LU0472753341.HKD","LU1815336760.USD","IE00BVYPNV92.GBP","LU0965509101.SGD","BK4604","SG9999015978.USD","BMED","LU2506952097.USD","IE00B5TLWC47.USD","LU0208291251.USD","LU1974910355.USD","LU0082616367.USD","LU1489326972.SGD","BK4528","LU2357627491.SGD","MEDX","SG9999014567.USD","LU1934455863.HKD","LU0823416689.USD","PPH","LU0642271901.SGD","LU1150488135.SGD","ADI","BK4597","LU2264538146.SGD","LU0106261372.USD","LU0476273544.USD","XDAT","LU1951198990.SGD","LU0158827948.USD","XLV","LU1116320737.USD","LU0097036916.USD","BBH","WOLF","LU0823421333.USD","LGHT","LU2360108059.USD","LU1989773731.SGD","LU2211815571.USD","LU2931357623.SGD","LU2347655156.SGD","LU1261432733.SGD","LU0511384066.AUD","IE00BLSP4452.SGD","LU1989772840.SGD","LU1917777945.USD","LU0109394709.USD","SMHX","IE000MB6IJN5.SGD","IE0002270589.USD","LU2125909593.SGD","IE0009356076.USD","LU2552382215.SGD","LU0289739343.SGD","IXJ","LU1674673691.USD","IE00B3S45H60.SGD","LU0056508442.USD","LU2355687059.USD","LU0314106906.USD","LU0203347892.USD","LU2125154778.USD","IE00BZ9MQY76.HKD","LU0211331839.USD","LU0980610538.SGD","LU0124676726.USD","BK4598","AIS","IE00BVYPNW00.USD","IBB","BK4599","LU0320765489.SGD","LU1037948541.HKD","LU2491050154.USD","LU1064131342.USD","LU2360107325.USD","CLOD","WISE","CRWD","BK4512","LU2461242641.AUD","LU2491049909.HKD","LU0689626769.HKD","LU2092937221.SGD","LU0266013472.USD","LU0312595415.SGD","LU1150488218.USD","LU1548497426.USD","LU1003077747.HKD","LU2237443465.HKD","TRUH","LU1551013342.USD","LU1496350502.SGD","IE00B19Z9Z06.USD","BK4548","BK4532","LU2023251221.USD","CLOU","IE000SO60NU8.SGD","LU2286300806.USD","IE00BZ199S13.USD","LU0553294199.USD","LU2129689605.HKD","SG9999014559.SGD","04332","PAWZ","LU2089985449.USD","LU0187121727.USD","LU2106854487.HKD","LU2517655291.USD","SG9999014542.SGD","EL","LU2290526834.HKD","IE00B4R5TH58.HKD","LU0128525929.USD","WCBR","LU1267930227.SGD","LU1861220033.SGD","LU1989764748.USD","BK4605","IE00BMPRXR70.SGD","LU0198837287.USD","IE000M9KFDE8.USD","IE00B3PB1722.GBP","BK4023","BK4581","LU1093756168.USD","IE000F7OJYX1.SGD","IE00BGHQF631.EUR","LU0265550946.USD","BK4613","LU0889565833.HKD","LU2237443549.SGD","TBXU","LU2129689431.USD","BK4185","IE00BLSP4239.USD","LU0823421416.USD","LU1057294990.SGD","LU2272731600.USD","LU1066051498.USD","LU1201861249.SGD","BK4554","LU0868494708.USD","LU2275660780.HKD","LU0058720904.USD","LU2404859667.USD","LU0477156953.USD","BK4504","FAI","LU1496350171.SGD","ABBV","LU0310800379.SGD","LU2347655073.USD","BK4607","FTXL","LU1244550221.USD","LU2298322129.HKD","LU0289739699.SGD","LU0823434740.USD","LU2244417387.USD","LU1988902786.USD","LU0289961442.SGD","LU0068578508.USD","PBE","LU2237438978.USD","LU1720051017.SGD","LU0820561818.USD","SG9999015341.SGD","LU0310800965.SGD","LU0823417737.USD","LU1778281490.HKD","LU0690374615.EUR","LU0130102774.USD","FDTX","SNOY","LU2265009873.SGD","LU0912757837.SGD","BK4155","AIFD","LU0965509283.SGD","LU0859254822.USD","LU0889565916.HKD","LU0882574055.USD","BK4561","LU1989771016.USD","LU0234570918.USD","AMGN","BILL","IE00BJT1NW94.SGD","LU2324357040.USD","RXL","LU1861219969.SGD","LU2250418816.HKD","LU1119994496.HKD","AIPI","LU1720051108.HKD","LU1506573853.SGD","IBBQ","WUGI","BK4592","BUG","LU0211327993.USD","SPAM","LU2468319806.SGD","BK4007","LU1670628061.USD","LU1061106388.HKD","SG9999011175.SGD","LU0320765992.SGD","LU1046421795.USD","LU1074936037.SGD","BK4534","LU0648001328.SGD","TJX","LU0965508806.USD","LU0823411888.USD","LU1934455194.USD","LU1116320901.HKD","LU2089984988.USD","LU0122379950.USD","LU0719512351.SGD","LU0395794307.EUR","WDAY","LU0070302665.USD","LU0545039389.USD","LU1066053197.SGD","LU0314104364.USD","LU2237443382.USD","LU2298321311.HKD","IE00B775SV38.USD","LU1430594728.SGD","LU0432979614.USD","HCA","IE00BBT3K403.USD","IE00BMPRXQ63.HKD","IE0034235188.USD","LU1066051225.USD","IDNA","LU2272731782.SGD","BK4183","LU2242652126.USD","LU0795875086.SGD","QQQA","IE00BKVL7J92.USD","BK4543","GTEK","LU1670711040.USD","IE00BJJMRZ35.SGD","LU0456855351.SGD","LU2360107168.USD","IE00B894F039.SGD","SG9999013999.USD","LU0170899867.USD","LU0210528500.USD","LU1861214812.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660473644","title":"福泰製藥(VRTX)股票8月19日收盤上漲4.48%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2660473644","media":"TradingKey中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660473644?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 04:16","pubTimestamp":1787170582,"startTime":"0","endTime":"0","summary":"• 在竞争对手临床试验宣告失败后，福泰制药股价飙升至历史新高。\n• 第二季度营收超出预期，公司同时上调了全年业绩指引。\n• 分析师纷纷给出看涨评级，平均目标价达 563.25 美元。","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262119125-market-movers-vrtx-20260819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU1585245621.USD","IE00B4R5TH58.HKD","LU2237438978.USD","LU2456880835.USD","LU0234570918.USD","BK4588","LU1035775433.USD","BIB","LU1069344957.HKD","LU2417539215.USD","BK4567","SG9999001176.SGD","LU0320765992.SGD","PBE","IE00B19Z9P08.USD","LU0058720904.USD","LU2236285917.USD","BK4532","TBXU","LU2462157665.USD","VRTX","IDNA","LU0289739699.SGD","LU1093756325.SGD","BBH","SGXZ57979304.SGD","LU0417517546.SGD","LU2468319806.SGD","IE00BJT1NW94.SGD","IBB","LU0109394709.USD","LU0823416689.USD","LU2362541273.HKD","IE00B19Z3B42.SGD","LU2362541513.USD","IE00BFTCPJ56.SGD","BK4139","LU1778281490.HKD","LU0432979614.USD","LU0079474960.USD","IE0009355771.USD","LU1674673428.USD","GNMX","IBBQ","LU1674673691.USD","LU0256863811.USD","IE00B19Z9Z06.USD","IE0002270589.USD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660113478","title":"吉利德科學(GILD)股票8月19日盤中上漲3.66%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2660113478","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660113478?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 03:17","pubTimestamp":1787167048,"startTime":"0","endTime":"0","summary":"• 得益于HIV产品组合增长加速，吉利德上调了全年销售指引。\n• 联邦法院颁布禁令阻止海外进口，以保护其核心市场份额。\n• 分析师给予“买入”评级，平均目标价为157.79美元。","market":"hk","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262118864-market-movers-gild-20260819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1023059063.AUD","LU0234570918.USD","LU0823416689.USD","IBBQ","IE00B7SZLL34.SGD","LU2324357040.USD","BK4588","LU0965509283.SGD","LU0320765992.SGD","IBB","IE00B19Z3581.USD","LU1934455277.USD","SG9999015978.USD","LU0058720904.USD","BK4550","BK4583","BK4139","BIB","IE0002270589.USD","LU1934455863.HKD","LU1057294990.SGD","LU1839511570.USD","SG9999015986.USD","LU0289739699.SGD","BK4568","BK4578","LU1066051498.USD","LU2468319806.SGD","GILD","BK4532","TBXU","BBH","LU1037948541.HKD","IE00B19Z3B42.SGD","LU1674673428.USD","SG9999015952.SGD","LU1934455194.USD","LU0965509010.AUD","LU1674673691.USD","MEDI","TMED","LU0965509101.SGD","SG9999015945.SGD","LU1585245621.USD","LU1778281490.HKD","LU0965508806.USD","BMED","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660819420","title":"安進(AMGN)股票8月19日盤中上漲3.19%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2660819420","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660819420?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 02:16","pubTimestamp":1787163383,"startTime":"0","endTime":"0","summary":"• Argus上调安进目标价，并重申“买入”评级。\n• 第二季度财务业绩超出华尔街的营收和盈利预期。\n• 技术指标显示 MACD 买入信号及 RSI 买入条件。","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262118749-market-movers-amgn-20260819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","LU1057294990.SGD","SG9999001440.SGD","IE00B2B36J28.USD","BK4139","LU0058720904.USD","LU0122379950.USD","LU0889565916.HKD","LU2468319806.SGD","IBBQ","BIB","IBB","LU1061106388.HKD","LU1571399168.USD","BK4534","BK4585","IE0002141913.USD","AMGN","BK4588","IE00BFTCPJ56.SGD","LU2112291526.USD","LU2089984988.USD","PBE","LU1023059063.AUD","TBXU","IE00B4R5TH58.HKD","LU0109394709.USD","BK4533","BK4581","BK4566","LU0320765992.SGD","LU1983299246.USD","LU0868494617.USD","LU0289739699.SGD","PJP","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU2242652126.USD","BBH","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105025052","title":"再生元製藥旗下Pasatru獲歐洲藥品管理局審評，全球申報在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1105025052","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105025052?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 02:00","pubTimestamp":1787162410,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其研发的药物Pasatru已被欧洲药品管理局纳入审评流程。与此同时，该公司正积极筹备在全球范围内提交该药物的上市申请。欧洲药品管理局的审评启动，为这款药物在欧洲地区的获批前景增添了重要砝码。业界分析认为，Pasatru若能顺利通过审评，有望为相关疾病领域带来新的治疗选择。再生元制药在创新药物研发领域深耕多年，此次针对Pasatru的全球布局，也彰显了其对这一候选药物商业潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0889565916.HKD","LU0823434740.USD","LU2089984988.USD","LU1974910355.USD","LU2023250504.SGD","BK4139","LU2468319806.SGD","BK4585","IBB","LU0289739699.SGD","BBH","REGN","LU0058720904.USD","TBXU","LU0320765992.SGD","LU2362540622.SGD","LU2106854487.HKD","LU1917777945.USD","LU0109394709.USD","LU0053666078.USD","LU2362541273.HKD","BK4588","LU0882574055.USD","IBBQ","LU0114720955.EUR","LU2237438978.USD","LU2362541513.USD","LU0823434583.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188134905","title":"再生元製藥獲FDA批准：Pasatru（Garetosmab-Grts）上市，治療成人進行性骨化性纖維發育不良","url":"https://stock-news.laohu8.com/highlight/detail?id=1188134905","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188134905?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 01:59","pubTimestamp":1787162353,"startTime":"0","endTime":"0","summary":"再生元制药公司今日宣布，其研发的新药Pasatru已获得美国食品药品监督管理局的正式批准，用于治疗成人进行性骨化性纤维发育不良。这一罕见疾病此前一直缺乏有效的治疗手段，此次获批为患者带来了新的希望。FDA的此次批准基于多项临床研究数据，结果显示Pasatru在减缓异位骨化进展方面表现出显著疗效，且安全性可控。未来，再生元制药计划进一步拓展Pasatru的适应症范围，并探索其在其他相关疾病中的潜在应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU1974910355.USD","LU2362541513.USD","BK4588","LU0053666078.USD","LU2023250504.SGD","BK4585","LU0114720955.EUR","LU0823434583.USD","IBB","LU1917777945.USD","LU0058720904.USD","LU2106854487.HKD","LU0889565916.HKD","LU2468319806.SGD","BBH","IBBQ","LU2362541273.HKD","LU0109394709.USD","REGN","LU2362540622.SGD","LU0823434740.USD","LU0823416689.USD","TBXU","LU0289739699.SGD","LU0882574055.USD","LU2237438978.USD","LU0320765992.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660585446","title":"瑞穗上調安進目標價至352美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660585446","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660585446?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 16:55","pubTimestamp":1787129710,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BFTCPJ56.SGD","LU0889565916.HKD","BBH","BK4534","LU1571399168.USD","LU0122379950.USD","BIB","IE00B2B36J28.USD","LU2089984988.USD","SG9999001440.SGD","BK4585","BK4533","UUP","UDN","IBBQ","LU1023059063.AUD","LU2468319806.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","LU2242646821.SGD","LU0109394709.USD","LU1061106388.HKD","IBB","LU0320765992.SGD","BK4566","LU2242652126.USD","TBXU","LU2112291526.USD","LU1057294990.SGD","AMGN","LU0058720904.USD","BK4139","IE0009355771.USD","BK4599","IE00BJJMRZ35.SGD","LU0289739699.SGD","IE00B4R5TH58.HKD","PJP","BK4581","LU0868494617.USD","LU1983299246.USD","PBE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660416851","title":"藥代違規進入診療區域！湘雅二醫院發藥品「停用函」，艾力斯、賽諾菲、安進、康蒂尼四藥企上「黑榜」","url":"https://stock-news.laohu8.com/highlight/detail?id=2660416851","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660416851?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 09:48","pubTimestamp":1787104101,"startTime":"0","endTime":"0","summary":"湘雅二医院方面向澎湃新闻表示，院方确有发该“协办函”。据此次公布的协办函，对几家涉事药企的处理决定颇为严厉。近年来，医药代表违规已不仅是行业道德问题，而是监管重点。此次湘雅二医院将企业列入购销负面清单，正是医院端落地上述政策的缩影。湘雅二医院相关负责人表示，自国家在2020年底建立医药代表备案制度，医院就积极响应国家政策，并不断完善内部制度和执行流程。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787103396417327872","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4585","LU1057294990.SGD","IBBQ","BK4533","LU2242652126.USD","IE0009355771.USD","LU2468319806.SGD","LU0320765992.SGD","BK4581","BK4139","IE00B2B36J28.USD","688578","IE00BJT1NW94.SGD","LU2089984988.USD","IE0002141913.USD","LU2112291526.USD","BK4534","LU1571399168.USD","IBB","BK4599","BK4566","IE00BJJMRZ35.SGD","BBH","LU1061106388.HKD","LU1023059063.AUD","SG9999001440.SGD","BIB","PBE","AMGN","BK0239","LU0868494617.USD","IE00B4R5TH58.HKD","BK4588","IE00BFTCPJ56.SGD","TBXU","LU0109394709.USD","PJP","LU0122379950.USD","LU2242646821.SGD","LU0889565916.HKD","LU0289739699.SGD","LU1983299246.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192416297","title":"TScan Therapeutics披露：安進將終止與其研究合作及許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1192416297","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192416297?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 05:04","pubTimestamp":1787087050,"startTime":"0","endTime":"0","summary":"值得注意的是，安进作为全球领先的生物制药公司，此举无疑将对TScan Therapeutics的研发管线及未来战略布局产生深远影响。TScan Therapeutics方面表示，将仔细评估这一变化对公司在研项目及整体运营带来的潜在影响。对于TScan Therapeutics而言，此番变故或许意味着需要重新校准其研发路径，并探索新的合作机会或资金来源以继续推进其创新疗法的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","LU0868494617.USD","LU1023059063.AUD","LU1057294990.SGD","LU2112291526.USD","IBBQ","LU0122379950.USD","LU1571399168.USD","LU0889565916.HKD","AMGN","PJP","BK4533","BK4599","IE0009355771.USD","SG9999001440.SGD","LU0289739699.SGD","LU2242652126.USD","BK4566","IBB","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4534","LU2089984988.USD","BIB","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4139","LU0109394709.USD","LU0320765992.SGD","BK4585","PBE","LU0058720904.USD","LU2468319806.SGD","LU1061106388.HKD","BK4588","BK4539","IE00BJJMRZ35.SGD","IE0002141913.USD","LU1983299246.USD","TCRX","BBH","LU2242646821.SGD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660491619","title":"吉利德科學(GILD)股票8月18日盤中上漲3.14%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2660491619","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660491619?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 02:16","pubTimestamp":1787076999,"startTime":"0","endTime":"0","summary":"• 联邦法院禁令阻止了吉利德关键HIV药物的海外进口。\n• 强劲的基础业务营收增长与上调业绩指引提振了市场乐观情绪。\n• 肿瘤领域的战略投资及机构看涨期权活动的活跃支撑了股价的上涨势头。","market":"hk","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262115765-market-movers-gild-20260818","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1023059063.AUD","LU0823416689.USD","IBBQ","IE00B7SZLL34.SGD","LU2324357040.USD","LU0114720955.EUR","LU0320765992.SGD","IBB","IE00B19Z3581.USD","SG9999015978.USD","LU0058720904.USD","BK4550","BK4583","BIB","BK4566","LU0109394709.USD","LU1934455863.HKD","LU1037948897.HKD","LU1839511570.USD","SG9999015986.USD","LU0289739699.SGD","BK4578","GILD","BK4532","LU1571399168.USD","TBXU","BBH","LU1037948541.HKD","LU2089984988.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU1674673428.USD","SG9999015952.SGD","LU1430594728.SGD","LU1061106388.HKD","BK4585","LU1674673691.USD","LU2087621335.USD","MEDI","TMED","LU0965509101.SGD","LU2112291526.USD","LU1585245621.USD","LU1778281490.HKD","LU0965508806.USD","BMED","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660332334","title":"EyePoint股價料將創下歷史最大跌幅，因其一款實驗性眼科藥物未能達到後期臨床試驗目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2660332334","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660332334?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 22:15","pubTimestamp":1786976114,"startTime":"0","endTime":"0","summary":"BUZZ-EyePoint股价料将创下历史最大跌幅，因其一款实验性眼科药物未能达到后期临床试验目标最新动态8月17日-**EyePoint公司（EYPT.O）股价暴跌71%至4.17美元，有望创下有史以来最大单日跌幅，并跌至2025年4月以来的最低点**这家药物开发商表示，其实验性眼科药物Duravyu在针对湿性年龄相关性黄斑变性（视力丧失的主要原因之一）患者开展的晚期临床试验中，未能达到主要目标","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4T44E101:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU1974910355.USD","LU2362541513.USD","BK4588","LU0053666078.USD","BK4007","LU2023250504.SGD","BK4585","LU0114720955.EUR","LU0823434583.USD","IBB","LU1917777945.USD","LU0058720904.USD","LU2106854487.HKD","LU0889565916.HKD","LU2468319806.SGD","BBH","IBBQ","LU2362541273.HKD","LU0109394709.USD","REGN","LU2362540622.SGD","LU0823434740.USD","LU0823416689.USD","TBXU","LU0289739699.SGD","LU0882574055.USD","LU2237438978.USD","LU0320765992.SGD","EYPT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":198,"code":"91000000","status":"200"}]}}